130 related articles for article (PubMed ID: 19233855)
1. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Mak KH; Bhatt DL; Shao M; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Montalescot G; Steg PG; Steinhubl SR; Fox KA; Topol EJ
Eur Heart J; 2009 Apr; 30(7):857-65. PubMed ID: 19233855
[TBL] [Abstract][Full Text] [Related]
2. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Mak KH; Bhatt DL; Shao M; Hankey GJ; Easton JD; Fox KA; Topol EJ
Am Heart J; 2009 Apr; 157(4):658-65. PubMed ID: 19332192
[TBL] [Abstract][Full Text] [Related]
3. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
5. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger JS; Bhatt DL; Steg PG; Steinhubl SR; Montalescot G; Shao M; Hacke W; Fox KA; Berger PB; Topol EJ; Lincoff AM
Am Heart J; 2011 Jul; 162(1):98-105.e1. PubMed ID: 21742095
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
7. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
[TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
9. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Booth J; Topol EJ;
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169314
[TBL] [Abstract][Full Text] [Related]
10. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
11. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
12. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW; Hankey GJ; Thom J; Bhatt DL; Steg PG; Montalescot G; Johnston SC; Steinhubl SR; Mak KH; Easton JD; Hamm C; Hu T; Fox KA; Topol EJ;
Circulation; 2008 Oct; 118(17):1705-12. PubMed ID: 18838564
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of atherothrombotic incidents. CHARISMA Study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance].
Erdmann E
Internist (Berl); 2006 Dec; 47(12):1295-7. PubMed ID: 17096154
[No Abstract] [Full Text] [Related]
14. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Hermann A; Dzialowski I; Koch R; Gahn G
J Neurol Sci; 2009 Sep; 284(1-2):155-7. PubMed ID: 19473668
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
Watson PD; Joy PS; Nkonde C; Hessen SE; Karalis DG
Am J Cardiol; 2009 Oct; 104(8):1052-4. PubMed ID: 19801023
[TBL] [Abstract][Full Text] [Related]
16. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
17. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Nie B; Ge HL; Jia DA; Yang SW; Yan ZX
Heart; 2009 Oct; 95(19):1587-92. PubMed ID: 19592387
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Spinler SA
Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
Wiederkehr D; Berenson K; Casciano R; Stern L; Makenbaeva D; Mozaffari E; Lamerato L; Corbelli J
Curr Med Res Opin; 2009 Sep; 25(9):2317-25. PubMed ID: 19635042
[TBL] [Abstract][Full Text] [Related]
20. Patients with peripheral arterial disease in the CHARISMA trial.
Cacoub PP; Bhatt DL; Steg PG; Topol EJ; Creager MA;
Eur Heart J; 2009 Jan; 30(2):192-201. PubMed ID: 19136484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
